肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Arvinas宣布启动1期临床研究，评估其靶向雌激素受体的PROTAC蛋白质降解剂ARV-471治疗乳腺癌的活性

2019-08-28 不详 MedSci原创

Arvinas雌激素受体PROTAC蛋白质降解剂ARV-471乳腺癌
关注

Arvinas公司一直致力于开发靶向蛋白质降解的新型药物，宣布启动第二个临床计划。ARV-471（一种口服雌激素受体（ER）靶向PROTAC蛋白质降解剂）的1期临床试验将评估ARV-471在局部晚期或转移性ER阳性/ HER2阴性乳腺癌患者中的安全性、耐受性和药代动力学。

Arvinas公司一直致力于开发靶向蛋白质降解的新型药物，宣布启动第二个临床计划。ARV-471（一种口服雌激素受体（ER）靶向PROTAC蛋白质降解剂）的1期临床试验将评估ARV-471在局部晚期或转移性ER阳性/ HER2阴性乳腺癌患者中的安全性、耐受性和药代动力学。

Arvinas首席医疗官Ronald Peck医学博士表示："ARV-471是一种有效的ER降解剂，在临床前模型中显示出显着的抗肿瘤活性，我们希望它能解决对目前标准治疗无法充分治疗的晚期ER阳性乳腺癌患者的重要需求。ARV-471是Arvinas第二个进入临床的靶向蛋白质降解剂，为我们公司和该领域带来了另一个令人兴奋和重要的发展。"

第1阶段临床试验将评估ARV-471的安全性，耐受性和药代动力学，并将包括其作为次要终点的药效学和抗肿瘤活性的测量。在临床前研究中，与目前的护理治疗方案相比，口服ARV-471显示出作为单一疗法和与CDK4 / 6抑制剂组合的改善体内 ER降解效力和抗肿瘤活性。在未来的试验中，该公司计划研究ARV-471作为单一药物和与其他方式（如CDK 4/6抑制剂）联合使用。

原始出处：


本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=951905, encodeId=8ea595190504, content=<a href='/topic/show?id=c6f814e5136' target=_blank style='color:#2F92EE;'>#PROTAC#</a>，未来肿瘤治疗的利器, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14751, encryptionId=c6f814e5136, topicName=PROTAC)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Mar 28 18:55:17 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780037, encodeId=4ed01e800376f, content=<a href='/topic/show?id=08832800c7' target=_blank style='color:#2F92EE;'>#ARV-471#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2800, encryptionId=08832800c7, topicName=ARV-471)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d1e370, createdName=yibei, createdTime=Fri Nov 01 01:53:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780040, encodeId=40f11e8004063, content=<a href='/topic/show?id=395b28032c' target=_blank style='color:#2F92EE;'>#Arvinas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2803, encryptionId=395b28032c, topicName=Arvinas)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Fri Mar 27 20:53:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765790, encodeId=c2cc1e6579099, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Apr 07 06:53:00 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033712, encodeId=edcd2033e126c, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17070, encryptionId=fc431e0708f, topicName=TAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Wed Sep 11 01:53:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811581, encodeId=717f181158169, content=<a href='/topic/show?id=180988e5793' target=_blank style='color:#2F92EE;'>#蛋白质降解剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88757, encryptionId=180988e5793, topicName=蛋白质降解剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sat Nov 30 15:53:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297092, encodeId=92fb129e092dc, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Aug 30 04:53:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503495, encodeId=196215034959f, content=<a href='/topic/show?id=59d798e61f0' target=_blank style='color:#2F92EE;'>#雌激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98761, encryptionId=59d798e61f0, topicName=雌激素受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6c9649886, createdName=surilei, createdTime=Fri Aug 30 04:53:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602193, encodeId=6d27160219303, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Aug 30 04:53:00 CST 2019, time=2019-08-30, status=1, ipAttribution=)]
    2021-03-28 病毒猎手

    #PROTAC#，未来肿瘤治疗的利器

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=951905, encodeId=8ea595190504, content=<a href='/topic/show?id=c6f814e5136' target=_blank style='color:#2F92EE;'>#PROTAC#</a>，未来肿瘤治疗的利器, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14751, encryptionId=c6f814e5136, topicName=PROTAC)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Mar 28 18:55:17 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780037, encodeId=4ed01e800376f, content=<a href='/topic/show?id=08832800c7' target=_blank style='color:#2F92EE;'>#ARV-471#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2800, encryptionId=08832800c7, topicName=ARV-471)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d1e370, createdName=yibei, createdTime=Fri Nov 01 01:53:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780040, encodeId=40f11e8004063, content=<a href='/topic/show?id=395b28032c' target=_blank style='color:#2F92EE;'>#Arvinas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2803, encryptionId=395b28032c, topicName=Arvinas)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Fri Mar 27 20:53:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765790, encodeId=c2cc1e6579099, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Apr 07 06:53:00 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033712, encodeId=edcd2033e126c, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17070, encryptionId=fc431e0708f, topicName=TAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Wed Sep 11 01:53:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811581, encodeId=717f181158169, content=<a href='/topic/show?id=180988e5793' target=_blank style='color:#2F92EE;'>#蛋白质降解剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88757, encryptionId=180988e5793, topicName=蛋白质降解剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sat Nov 30 15:53:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297092, encodeId=92fb129e092dc, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Aug 30 04:53:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503495, encodeId=196215034959f, content=<a href='/topic/show?id=59d798e61f0' target=_blank style='color:#2F92EE;'>#雌激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98761, encryptionId=59d798e61f0, topicName=雌激素受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6c9649886, createdName=surilei, createdTime=Fri Aug 30 04:53:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602193, encodeId=6d27160219303, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Aug 30 04:53:00 CST 2019, time=2019-08-30, status=1, ipAttribution=)]
    2019-11-01 yibei

    #ARV-471#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=951905, encodeId=8ea595190504, content=<a href='/topic/show?id=c6f814e5136' target=_blank style='color:#2F92EE;'>#PROTAC#</a>，未来肿瘤治疗的利器, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14751, encryptionId=c6f814e5136, topicName=PROTAC)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Mar 28 18:55:17 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780037, encodeId=4ed01e800376f, content=<a href='/topic/show?id=08832800c7' target=_blank style='color:#2F92EE;'>#ARV-471#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2800, encryptionId=08832800c7, topicName=ARV-471)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d1e370, createdName=yibei, createdTime=Fri Nov 01 01:53:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780040, encodeId=40f11e8004063, content=<a href='/topic/show?id=395b28032c' target=_blank style='color:#2F92EE;'>#Arvinas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2803, encryptionId=395b28032c, topicName=Arvinas)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Fri Mar 27 20:53:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765790, encodeId=c2cc1e6579099, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Apr 07 06:53:00 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033712, encodeId=edcd2033e126c, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17070, encryptionId=fc431e0708f, topicName=TAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Wed Sep 11 01:53:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811581, encodeId=717f181158169, content=<a href='/topic/show?id=180988e5793' target=_blank style='color:#2F92EE;'>#蛋白质降解剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88757, encryptionId=180988e5793, topicName=蛋白质降解剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sat Nov 30 15:53:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297092, encodeId=92fb129e092dc, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Aug 30 04:53:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503495, encodeId=196215034959f, content=<a href='/topic/show?id=59d798e61f0' target=_blank style='color:#2F92EE;'>#雌激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98761, encryptionId=59d798e61f0, topicName=雌激素受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6c9649886, createdName=surilei, createdTime=Fri Aug 30 04:53:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602193, encodeId=6d27160219303, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Aug 30 04:53:00 CST 2019, time=2019-08-30, status=1, ipAttribution=)]
    2020-03-27 楚秀娟

    #Arvinas#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=951905, encodeId=8ea595190504, content=<a href='/topic/show?id=c6f814e5136' target=_blank style='color:#2F92EE;'>#PROTAC#</a>，未来肿瘤治疗的利器, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14751, encryptionId=c6f814e5136, topicName=PROTAC)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Mar 28 18:55:17 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780037, encodeId=4ed01e800376f, content=<a href='/topic/show?id=08832800c7' target=_blank style='color:#2F92EE;'>#ARV-471#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2800, encryptionId=08832800c7, topicName=ARV-471)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d1e370, createdName=yibei, createdTime=Fri Nov 01 01:53:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780040, encodeId=40f11e8004063, content=<a href='/topic/show?id=395b28032c' target=_blank style='color:#2F92EE;'>#Arvinas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2803, encryptionId=395b28032c, topicName=Arvinas)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Fri Mar 27 20:53:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765790, encodeId=c2cc1e6579099, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Apr 07 06:53:00 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033712, encodeId=edcd2033e126c, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17070, encryptionId=fc431e0708f, topicName=TAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Wed Sep 11 01:53:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811581, encodeId=717f181158169, content=<a href='/topic/show?id=180988e5793' target=_blank style='color:#2F92EE;'>#蛋白质降解剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88757, encryptionId=180988e5793, topicName=蛋白质降解剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sat Nov 30 15:53:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297092, encodeId=92fb129e092dc, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Aug 30 04:53:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503495, encodeId=196215034959f, content=<a href='/topic/show?id=59d798e61f0' target=_blank style='color:#2F92EE;'>#雌激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98761, encryptionId=59d798e61f0, topicName=雌激素受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6c9649886, createdName=surilei, createdTime=Fri Aug 30 04:53:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602193, encodeId=6d27160219303, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Aug 30 04:53:00 CST 2019, time=2019-08-30, status=1, ipAttribution=)]
    2020-04-07 柳叶一刀

    #白质#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=951905, encodeId=8ea595190504, content=<a href='/topic/show?id=c6f814e5136' target=_blank style='color:#2F92EE;'>#PROTAC#</a>，未来肿瘤治疗的利器, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14751, encryptionId=c6f814e5136, topicName=PROTAC)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Mar 28 18:55:17 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780037, encodeId=4ed01e800376f, content=<a href='/topic/show?id=08832800c7' target=_blank style='color:#2F92EE;'>#ARV-471#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2800, encryptionId=08832800c7, topicName=ARV-471)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d1e370, createdName=yibei, createdTime=Fri Nov 01 01:53:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780040, encodeId=40f11e8004063, content=<a href='/topic/show?id=395b28032c' target=_blank style='color:#2F92EE;'>#Arvinas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2803, encryptionId=395b28032c, topicName=Arvinas)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Fri Mar 27 20:53:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765790, encodeId=c2cc1e6579099, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Apr 07 06:53:00 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033712, encodeId=edcd2033e126c, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17070, encryptionId=fc431e0708f, topicName=TAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Wed Sep 11 01:53:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811581, encodeId=717f181158169, content=<a href='/topic/show?id=180988e5793' target=_blank style='color:#2F92EE;'>#蛋白质降解剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88757, encryptionId=180988e5793, topicName=蛋白质降解剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sat Nov 30 15:53:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297092, encodeId=92fb129e092dc, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Aug 30 04:53:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503495, encodeId=196215034959f, content=<a href='/topic/show?id=59d798e61f0' target=_blank style='color:#2F92EE;'>#雌激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98761, encryptionId=59d798e61f0, topicName=雌激素受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6c9649886, createdName=surilei, createdTime=Fri Aug 30 04:53:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602193, encodeId=6d27160219303, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Aug 30 04:53:00 CST 2019, time=2019-08-30, status=1, ipAttribution=)]
    2019-09-11 grace5700

    #TAC#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=951905, encodeId=8ea595190504, content=<a href='/topic/show?id=c6f814e5136' target=_blank style='color:#2F92EE;'>#PROTAC#</a>，未来肿瘤治疗的利器, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14751, encryptionId=c6f814e5136, topicName=PROTAC)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Mar 28 18:55:17 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780037, encodeId=4ed01e800376f, content=<a href='/topic/show?id=08832800c7' target=_blank style='color:#2F92EE;'>#ARV-471#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2800, encryptionId=08832800c7, topicName=ARV-471)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d1e370, createdName=yibei, createdTime=Fri Nov 01 01:53:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780040, encodeId=40f11e8004063, content=<a href='/topic/show?id=395b28032c' target=_blank style='color:#2F92EE;'>#Arvinas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2803, encryptionId=395b28032c, topicName=Arvinas)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Fri Mar 27 20:53:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765790, encodeId=c2cc1e6579099, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Apr 07 06:53:00 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033712, encodeId=edcd2033e126c, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17070, encryptionId=fc431e0708f, topicName=TAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Wed Sep 11 01:53:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811581, encodeId=717f181158169, content=<a href='/topic/show?id=180988e5793' target=_blank style='color:#2F92EE;'>#蛋白质降解剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88757, encryptionId=180988e5793, topicName=蛋白质降解剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sat Nov 30 15:53:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297092, encodeId=92fb129e092dc, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Aug 30 04:53:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503495, encodeId=196215034959f, content=<a href='/topic/show?id=59d798e61f0' target=_blank style='color:#2F92EE;'>#雌激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98761, encryptionId=59d798e61f0, topicName=雌激素受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6c9649886, createdName=surilei, createdTime=Fri Aug 30 04:53:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602193, encodeId=6d27160219303, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Aug 30 04:53:00 CST 2019, time=2019-08-30, status=1, ipAttribution=)]
    2019-11-30 qidongfanjian

    #蛋白质降解剂#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=951905, encodeId=8ea595190504, content=<a href='/topic/show?id=c6f814e5136' target=_blank style='color:#2F92EE;'>#PROTAC#</a>，未来肿瘤治疗的利器, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14751, encryptionId=c6f814e5136, topicName=PROTAC)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Mar 28 18:55:17 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780037, encodeId=4ed01e800376f, content=<a href='/topic/show?id=08832800c7' target=_blank style='color:#2F92EE;'>#ARV-471#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2800, encryptionId=08832800c7, topicName=ARV-471)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d1e370, createdName=yibei, createdTime=Fri Nov 01 01:53:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780040, encodeId=40f11e8004063, content=<a href='/topic/show?id=395b28032c' target=_blank style='color:#2F92EE;'>#Arvinas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2803, encryptionId=395b28032c, topicName=Arvinas)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Fri Mar 27 20:53:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765790, encodeId=c2cc1e6579099, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Apr 07 06:53:00 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033712, encodeId=edcd2033e126c, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17070, encryptionId=fc431e0708f, topicName=TAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Wed Sep 11 01:53:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811581, encodeId=717f181158169, content=<a href='/topic/show?id=180988e5793' target=_blank style='color:#2F92EE;'>#蛋白质降解剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88757, encryptionId=180988e5793, topicName=蛋白质降解剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sat Nov 30 15:53:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297092, encodeId=92fb129e092dc, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Aug 30 04:53:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503495, encodeId=196215034959f, content=<a href='/topic/show?id=59d798e61f0' target=_blank style='color:#2F92EE;'>#雌激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98761, encryptionId=59d798e61f0, topicName=雌激素受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6c9649886, createdName=surilei, createdTime=Fri Aug 30 04:53:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602193, encodeId=6d27160219303, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Aug 30 04:53:00 CST 2019, time=2019-08-30, status=1, ipAttribution=)]
    2019-08-30 cmj8wellington

    #蛋白质#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=951905, encodeId=8ea595190504, content=<a href='/topic/show?id=c6f814e5136' target=_blank style='color:#2F92EE;'>#PROTAC#</a>，未来肿瘤治疗的利器, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14751, encryptionId=c6f814e5136, topicName=PROTAC)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Mar 28 18:55:17 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780037, encodeId=4ed01e800376f, content=<a href='/topic/show?id=08832800c7' target=_blank style='color:#2F92EE;'>#ARV-471#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2800, encryptionId=08832800c7, topicName=ARV-471)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d1e370, createdName=yibei, createdTime=Fri Nov 01 01:53:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780040, encodeId=40f11e8004063, content=<a href='/topic/show?id=395b28032c' target=_blank style='color:#2F92EE;'>#Arvinas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2803, encryptionId=395b28032c, topicName=Arvinas)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Fri Mar 27 20:53:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765790, encodeId=c2cc1e6579099, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Apr 07 06:53:00 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033712, encodeId=edcd2033e126c, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17070, encryptionId=fc431e0708f, topicName=TAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Wed Sep 11 01:53:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811581, encodeId=717f181158169, content=<a href='/topic/show?id=180988e5793' target=_blank style='color:#2F92EE;'>#蛋白质降解剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88757, encryptionId=180988e5793, topicName=蛋白质降解剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sat Nov 30 15:53:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297092, encodeId=92fb129e092dc, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Aug 30 04:53:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503495, encodeId=196215034959f, content=<a href='/topic/show?id=59d798e61f0' target=_blank style='color:#2F92EE;'>#雌激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98761, encryptionId=59d798e61f0, topicName=雌激素受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6c9649886, createdName=surilei, createdTime=Fri Aug 30 04:53:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602193, encodeId=6d27160219303, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Aug 30 04:53:00 CST 2019, time=2019-08-30, status=1, ipAttribution=)]
    2019-08-30 surilei

    #雌激素受体#

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=951905, encodeId=8ea595190504, content=<a href='/topic/show?id=c6f814e5136' target=_blank style='color:#2F92EE;'>#PROTAC#</a>，未来肿瘤治疗的利器, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14751, encryptionId=c6f814e5136, topicName=PROTAC)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Mar 28 18:55:17 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780037, encodeId=4ed01e800376f, content=<a href='/topic/show?id=08832800c7' target=_blank style='color:#2F92EE;'>#ARV-471#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2800, encryptionId=08832800c7, topicName=ARV-471)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d1e370, createdName=yibei, createdTime=Fri Nov 01 01:53:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780040, encodeId=40f11e8004063, content=<a href='/topic/show?id=395b28032c' target=_blank style='color:#2F92EE;'>#Arvinas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2803, encryptionId=395b28032c, topicName=Arvinas)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Fri Mar 27 20:53:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765790, encodeId=c2cc1e6579099, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Apr 07 06:53:00 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033712, encodeId=edcd2033e126c, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17070, encryptionId=fc431e0708f, topicName=TAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Wed Sep 11 01:53:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811581, encodeId=717f181158169, content=<a href='/topic/show?id=180988e5793' target=_blank style='color:#2F92EE;'>#蛋白质降解剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88757, encryptionId=180988e5793, topicName=蛋白质降解剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sat Nov 30 15:53:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297092, encodeId=92fb129e092dc, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Aug 30 04:53:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503495, encodeId=196215034959f, content=<a href='/topic/show?id=59d798e61f0' target=_blank style='color:#2F92EE;'>#雌激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98761, encryptionId=59d798e61f0, topicName=雌激素受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6c9649886, createdName=surilei, createdTime=Fri Aug 30 04:53:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602193, encodeId=6d27160219303, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Aug 30 04:53:00 CST 2019, time=2019-08-30, status=1, ipAttribution=)]
    2019-08-30 sunylz

    #PRO#

    0